Pregabalin (Lyrica) in Insurance Claims
Understanding pregabalin prescribing in insurance claims. Learn about appropriate use, misuse risks, and when to refer for medication review.
Published: 3 April 2026 | Updated: 3 April 2026
What is Pregabalin?
Pregabalin (marketed as Lyrica) is a gabapentinoid medication used primarily for neuropathic pain, fibromyalgia, and generalised anxiety disorder. It's not an opioid; instead, it works on calcium channels in the nervous system, reducing abnormal nerve firing that causes neuropathic pain. In insurance claims, pregabalin appears frequently for nerve pain arising from workplace injuries, road accidents, or complications of those injuries.
Pregabalin is available in capsules (75, 150, 225, 300 mg) and a liquid formulation. Typical dosing for neuropathic pain ranges from 150-600 mg daily in divided doses. Unlike opioids, pregabalin doesn't carry opioid-like addiction potential; however, it does have misuse potential and can cause dependence with regular use.
When is Pregabalin Appropriate in Insurance Claims?
Evidence-Based Indications
- Neuropathic pain from injury: Nerve damage or pain from a compensable injury (e.g., crush injury, nerve compression, spinal nerve involvement). Pregabalin is first-line treatment for many neuropathic pain conditions.
- Spinal cord injury: Neuropathic pain after spinal cord damage responds well to pregabalin.
- Post-herpetic neuralgia: Nerve pain persisting after shingles. This is one of pregabalin's most evidence-supported indications.
- Phantom limb pain: After amputation, pregabalin reduces neuropathic pain.
- Fibromyalgia: Widespread pain with neuropathic features; pregabalin is evidence-based.
- Generalised anxiety disorder: Pregabalin is approved for anxiety, and some claimants with injury-related anxiety benefit from it.
Situations Warranting Extra Scrutiny
- Pregabalin prescribed for purely musculoskeletal pain without neuropathic features (evidence is weaker).
- Very high doses (above 600 mg daily) without documented neuropathic indication or specialist assessment.
- Pregabalin combined with opioids and benzodiazepines, particularly at high doses (high-risk polypharmacy).
- Rapid dose escalation without documented clinical reassessment.
- Pregabalin prescribed to a claimant with known substance use disorder without documented safety plan or specialist oversight.
- Long-term pregabalin prescribed without documented pain improvement or functional gains.
Pregabalin Misuse: A Growing Concern
Pregabalin is increasingly misused, particularly in people with opioid use disorders or other substance use issues. It produces mild euphoria at higher doses and enhances the effect of opioids, creating a "high" that some people seek. In Australian and New Zealand prisons, pregabalin is a significant contraband drug. In your claims, claimants with substance use history are at higher risk of misuse.
Signs of Pregabalin Misuse in Claims
- Rapid dose escalation (increasing 150-300 mg every few weeks) without documented clinical justification.
- Doses consistently above 600 mg daily, particularly with inadequate pain relief.
- Claimant on pregabalin plus opioids plus benzodiazepines; particularly high-risk polypharmacy for intoxication seeking.
- Frequent requests for early repeats or lost prescriptions.
- Doctor shopping: seeking pregabalin from multiple prescribers.
- Known substance use disorder or previous addiction history with minimal documented pain condition.
- Claimant reports euphoric or intoxicating effects from pregabalin; this is a red flag for misuse.
Pregabalin and Polypharmacy Risks
The Dangerous Triad
Pregabalin plus opioids plus benzodiazepines is a combination that significantly increases overdose risk, respiratory depression, and serious adverse effects. When all three are combined, particularly at high doses, the risk profile escalates dramatically. If your claimant is on this combination, immediate pharmacy review is warranted. Many clinical guidelines recommend avoiding this combination or limiting it to very specific scenarios with specialist oversight.
Pregabalin and Alcohol
Alcohol combined with pregabalin increases CNS depression (sedation, cognitive impairment) and overdose risk. Claimants with alcohol use should be counseled to avoid concurrent use, or the combination warrants careful monitoring.
When Should You Refer for Pharmacy Review?
Step 1: Confirm the Neuropathic Indication
Is there documented neuropathic pain? Is pregabalin being used for an evidence-based indication (neuropathic pain, fibromyalgia, anxiety), or is it prescribed for musculoskeletal pain without neuropathic features? If the latter, question whether pregabalin is the best choice; non-opioid analgesics may be more appropriate.
Step 2: Assess the Dose and Escalation Pattern
What is the current dose? Has it escalated rapidly without documented clinical reasons? Doses persistently above 600 mg daily warrant assessment, particularly if pain relief isn't proportionate to the dose. Rapid escalation suggests either inadequate pain control (requiring multimodal pain management reassessment) or misuse (requiring substance use intervention).
Step 3: Check for High-Risk Polypharmacy
Is the claimant on pregabalin plus opioids plus benzodiazepines? This is high-risk. Refer for immediate assessment and likely deprescribing of one agent or significant dose reduction.
Step 4: Assess Substance Use History and Misuse Risk
Does the claimant have a history of substance use disorder? If so, is there a documented safety plan, urine drug screening, or specialist oversight? If pregabalin is being prescribed to someone with substance use history without these safeguards, risk of misuse is elevated.
Red Flags in Pregabalin Claims
- Pregabalin prescribed for purely musculoskeletal pain without neuropathic features (evidence limited).
- Rapid dose escalation (increasing 150+ mg every few weeks) without clinical justification.
- Doses consistently above 600 mg daily without exceptional clinical circumstances.
- Pregabalin combined with opioids and benzodiazepines, particularly at high doses.
- Claimant with substance use disorder on high-dose pregabalin without documented safety measures (urine drug screening, specialist oversight).
- Frequent requests for early repeats, lost prescriptions, or doctor shopping.
- Claimant reports euphoric or intoxicating effects from pregabalin.
- No documented pain improvement or functional gains despite long-term pregabalin use at high doses.
- Prescriber lacks experience in pain management or substance use disorder; prescribing seems inappropriate.
Pregabalin vs. Opioids for Neuropathic Pain
From your insurer's perspective, pregabalin is generally preferable to opioids for neuropathic pain. Pregabalin is evidence-based for nerve pain, carries lower addiction potential than opioids, and can be combined with non-opioid pain management strategies. If your claimant has neuropathic pain and is on high-dose opioids, consider whether transitioning to optimised pregabalin dosing (possibly with gabapentin, another nerve pain agent) could reduce opioid requirement and improve outcomes. Many claimants benefit from this transition.
Questions to Ask Your Pharmacist
- Is there documented neuropathic pain? What is the specific neuropathic diagnosis?
- Is pregabalin at an evidence-based dose for this indication, or has it escalated excessively?
- What is the documented pain relief achieved? Is the dose justified by outcomes?
- Are there high-risk drug combinations (pregabalin plus opioids plus benzodiazepines)?
- Does the claimant have a substance use disorder history? If so, are there safety measures in place (urine drug screening, specialist oversight)?
- Are there signs of misuse (rapid escalation, intoxication-seeking, doctor shopping)?
- What non-pharmacological pain management strategies are in place (physiotherapy, psychology)?
- Could the claimant transition to a lower pregabalin dose combined with optimised non-opioid pain management?
- Is there documented monitoring and regular review of pregabalin efficacy and safety?
Deprescribing Pregabalin
If your claimant is on high-dose pregabalin without clear benefit or with signs of misuse, gradual deprescribing is recommended. Sudden cessation can cause withdrawal symptoms (rebound pain, anxiety, insomnia). Typical tapering involves reducing pregabalin by 50-100 mg every 1-2 weeks, with concurrent intensification of non-pharmacological pain management. For claimants with substance use history, deprescribing should be supported by specialist counseling and alternative pain management strategies to prevent relapse.
Summary: Your Decision Framework
Pregabalin is appropriate for neuropathic pain and is often a better choice than opioids for nerve-related pain in insurance claims. However, doses should be evidence-based, escalation should be justified, and high-risk polypharmacy combinations (pregabalin plus opioids plus benzodiazepines) should be actively avoided. Claimants with substance use history require careful monitoring. If your claimant is on high-dose pregabalin without clear neuropathic indication, with rapid escalation, or in combination with opioids and benzodiazepines, refer for pharmacy review. Your pharmacist can assess whether doses are justified, identify misuse risk, and recommend safer pain management approaches.
Reviewing pregabalin in your claims?
IMM's pharmacists assess pregabalin use in insurance claims, identifying appropriate indications, misuse risk, dangerous polypharmacy combinations, and opportunities to transition to safer, evidence-based pain management that reduces medication-related risks.
Request a Medication Review
